Amplia’s Cancer Drug Trial Advances Successfully

Amplia Therapeutics Ltd. (AU:ATX) has released an update.

Amplia Therapeutics Ltd. reports successful progression in their Phase 2a ACCENT trial for advanced pancreatic cancer, with six patients achieving the required reduction in tumor size using their drug narmafotinib combined with chemotherapy. This positive outcome paves the way for the recruitment of an additional 24 patients, aiming for a total of 50 participants in the study. An interim analysis of the trial data is forthcoming, while the trial’s completion is expected by the end of Q1 2025.

For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.